Submitted:
25 October 2023
Posted:
26 October 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Cocaine Locomotor Sensitization
2.2. Effects of Cocaine Sensitization on AMPK Protein Levels
2.3. Effects of Metformin Pretreatment on Cocaine Induced Locomotion and Sensitization
2.4. Effects of Metformin Pretreatment Followed by Cocaine on AMPK Protein Levels
3. Discussion
4. Materials and Methods
4.1. Subjects
4.2. Chemicals
4.3. Cocaine Sensitization
4.3.1. Experiment 1:
4.3.2. Experiment 2:
4.4. Euthanasia, Tissue Extraction, Preparation and Western Blotting
4.5. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- J. D. Steketee and P. W. Kalivas, “Drug Wanting: Behavioral Sensitization and Relapse to Drug-Seeking Behavior,” Pharmacol. Rev., vol. 63, no. 2, pp. 348–365. [CrossRef]
- R. M. Post and H. Rose, “Increasing effects of repetitive cocaine administration in the rat,” Nature, vol. 260, no. 5553, pp. 731–732, Apr. 1976. [CrossRef]
- D. Henry and F. White, “The persistence of behavioral sensitization to cocaine parallels enhanced inhibition of nucleus accumbens neurons,” J. Neurosci., vol. 15, no. 9, pp. 6287–6299, Sep. 1995. [CrossRef]
- S. Schenk, “Sensitization to Cocaine’s Reinforcing Effects Produced by Various Cocaine Pretreatment Regimens in Rats,” Pharmacol. Biochem. Behav., vol. 66, no. 4, pp. 765–770, Aug. 2000. [CrossRef]
- B. H. Mandt, S. Schenk, N. R. Zahniser, and R. M. Allen, “Individual differences in cocaine-induced locomotor activity in male Sprague–Dawley rats and their acquisition of and motivation to self-administer cocaine,” Psychopharmacology (Berl.), vol. 201, no. 2, pp. 195–202, Dec. 2008. [CrossRef]
- C. R. Ferrario, G. Gorny, H. S. Crombag, Y. Li, B. Kolb, and T. E. Robinson, “Neural and Behavioral Plasticity Associated with the Transition from Controlled to Escalated Cocaine Use,” Biol. Psychiatry, vol. 58, no. 9, pp. 751–759, Nov. 2005. [CrossRef]
- Boileau et al., “Modeling Sensitization to Stimulants in Humans: An [ 11 C]Raclopride/Positron Emission Tomography Study in Healthy Men,” Arch. Gen. Psychiatry, vol. 63, no. 12, Dec. 2006. [CrossRef]
- P. W. Kalivas and P. Duffy, “Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals,” J. Neurosci., vol. 13, no. 1, p. 266 LP – 275, Jan. 1993. [CrossRef]
- L. H. Parsons and J. B. Justice, “Serotonin and Dopamine Sensitization in the Nucleus Accumbens, Ventral Tegmental Area, and Dorsal Raphe Nucleus Following Repeated Cocaine Administration,” J. Neurochem., vol. 61, no. 5, pp. 1611–1619, Nov. 1993. [CrossRef]
- R. C. Pierce, K. Bell, P. Duffy, and P. W. Kalivas, “Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization,” J. Neurosci., vol. 16, no. 4, p. 1550 LP – 1560, Feb. 1996. [CrossRef]
- M. S. Reid and S. P. Berger, “Evidence for sensitization of cocaine-induced nucleus accumbens glutamate release:,” NeuroReport, vol. 7, no. 7, pp. 1325–1329, May 1996. 19 May. [CrossRef]
- V. Parikh et al., “Cocaine-induced neuroadaptations in the dorsal striatum: Glutamate dynamics and behavioral sensitization,” Neurochem. Int., vol. 75, pp. 54–65, Sep. 2014. [CrossRef]
- K. Liu and J. D. Steketee, “Repeated exposure to cocaine alters medial prefrontal cortex dopamine D2-like receptor modulation of glutamate and dopamine neurotransmission within the mesocorticolimbic system: Sensitization and cortical dopamine receptors,” J. Neurochem., vol. 119, no. 2, pp. 332–341, Oct. 2011. [CrossRef]
- H. Li et al., “mTOR regulates cocaine-induced behavioural sensitization through the SynDIG1–GluA2 interaction in the nucleus accumbens,” Acta Pharmacol. Sin., vol. 43, no. 2, pp. 295–306, Feb. 2022. [CrossRef]
- S. M. Ferguson, S. Fasano, P. Yang, R. Brambilla, and T. E. Robinson, “Knockout of ERK1 Enhances Cocaine-Evoked Immediate Early Gene Expression and Behavioral Plasticity,” Neuropsychopharmacology, vol. 31, no. 12, pp. 2660–2668, Dec. 2006. [CrossRef]
- C. A. Hoeffer and E. Klann, “mTOR signaling: At the crossroads of plasticity, memory and disease,” Trends Neurosci., vol. 33, no. 2, pp. 67–75, Feb. 2010,. [CrossRef]
- K. Inoki, T. Zhu, and K.-L. Guan, “TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival,” Cell, vol. 115, no. 5, pp. 577–590, Nov. 2003. [CrossRef]
- D. M. Gwinn et al., “AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint,” Mol. Cell, vol. 30, no. 2, pp. 214–226, Apr. 2008. [CrossRef]
- N. X. Y. Ling et al., “mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress,” Nat. Metab., vol. 2, no. 1, pp. 41–49, Jan. 2020. [CrossRef]
- D. G. Hardie, “AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels.,” Annu. Rev. Nutr., vol. 34, pp. 31–55, 2014. [CrossRef]
- R. Muraleedharan and B. Dasgupta, “AMPK in the brain: its roles in glucose and neural metabolism,” FEBS J., vol. 289, no. 8, pp. 2247–2262, Apr. 2022. [CrossRef]
- J. López-Gambero, F. Rodríguez de Fonseca, and J. Suárez, “Energy sensors in drug addiction: A potential therapeutic target.,” Addict. Biol., vol. 26, no. 2, p. e12936. [CrossRef]
- M. Domise and V. Vingtdeux, “AMPK in Neurodegenerative Diseases,” in AMP-activated Protein Kinase, vol. 107, M. D. Cordero and B. Viollet, Eds., in Experientia Supplementum, vol. 107. , Cham: Springer International Publishing, 2016, pp. 153–177. [CrossRef]
- S. Xu and U. G. Kang, “Region-specific activation of the AMPK system by cocaine: The role of D1 and D2 receptors.,” Pharmacol. Biochem. Behav., vol. 146–147, pp. 28–34, 2016. [CrossRef]
- X.-J. Gao et al., “AMPK signaling in the nucleus accumbens core mediates cue-induced reinstatement of cocaine seeking.,” Sci. Rep., vol. 7, no. 1, p. 1038, Apr. 2017. [CrossRef]
- X.-X. Liu et al., “Novel role of AMPK in cocaine reinforcement via regulating CRTC1,” Transl. Psychiatry, vol. 12, no. 1, p. 530, Dec. 2022. [CrossRef]
- G. Rena, D. G. Hardie, and E. R. Pearson, “The mechanisms of action of metformin.,” Diabetologia, vol. 60, no. 9, pp. 1577–1585, Sep. 2017. [CrossRef]
- Y. Wang et al., “Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK,” Cell Rep, vol. 29, no. 6, pp. 1511-1523.e5, Nov. 2019. [CrossRef]
- Chan et al., “Metformin in nucleus accumbens core reduces cue-induced cocaine seeking in male and female rats,” Addict. Biol., vol. 27, no. 3, p. 2021.09.05.458975, May 2022. [CrossRef]
- L. C. Smith and O. George, “Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models,” Neuropharmacology, vol. 178, p. 108225, Nov. 2020. [CrossRef]
- S. K. Paul, K. Klein, A. Majeed, and K. Khunti, “Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes: 在新诊断的2型糖尿病患者中吸烟以及同时使用二甲双胍与心血管事件以及死亡率之间的关系,” J. Diabetes, vol. 8, no. 3, pp. 354–362, May 2016. 16. [CrossRef]
- S. Prasad et al., “Role of Nrf2 and protective effects of Metformin against tobacco smoke-induced cerebrovascular toxicity,” Redox Biol., vol. 12, pp. 58–69, Aug. 2017. [CrossRef]
- C. Corcoran and T. F. Jacobs, “Metformin,” in StatPearls, Treasure Island (FL): StatPearls Publishing, 2023. Accessed: Sep. 26, 2023. [Online]. Available online: http://www.ncbi.nlm.nih.gov/books/NBK518983/.
- R. Ozburn and S. M. Spencer, “Repurposing anti-inflammatory medications for alcohol and substance use disorders,” Neuropsychopharmacology, pp. s41386-023-01696-z, Aug. 2023. [CrossRef]
- G. Wang, S. Amato, J. Gilbert, and H.-Y. Man, “Resveratrol up-regulates AMPA receptor expression via AMP-activated protein kinase-mediated protein translation,” Neuropharmacology, vol. 95, pp. 144–153, Aug. 2015. [CrossRef]
- L. Wegman-Points et al., “Subcellular partitioning of protein kinase activity revealed by functional kinome profiling,” Sci. Rep., vol. 12, no. 1, p. 17300, Oct. 2022. [CrossRef]
- M. Catalfio, T. L. Fetterly, A. M. Nieto, T. E. Robinson, and C. R. Ferrario, “Cocaine-induced sensitization and glutamate plasticity in the nucleus accumbens core: effects of sex,” Biol. Sex Differ., vol. 14, no. 1, p. 41, Jun. 2023. [CrossRef]
- S. Chauhan, L. Zhuang, and B. Gan, “Spatial control of AMPK signaling at subcellular compartments,” Crit. Rev. Biochem. Mol. Biol., vol. 55, no. 1, pp. 17–32, Jan. 2020. [CrossRef]
- Q. Afinanisa, M. K. Cho, and H.-A. Seong, “AMPK Localization: A Key to Differential Energy Regulation,” Int. J. Mol. Sci., vol. 22, no. 20, p. 10921, Oct. 2021. [CrossRef]
- L. Wang, Y. Cai, and X. Fan, “Metformin Administration During Early Postnatal Life Rescues Autistic-Like Behaviors in the BTBR T+ Itpr3tf/J Mouse Model of Autism,” Front. Behav. Neurosci., vol. 12, p. 290, Nov. 2018. [CrossRef]
- M. Suwa, T. Egashira, H. Nakano, H. Sasaki, and S. Kumagai, “Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo,” J. Appl. Physiol., vol. 101, no. 6, pp. 1685–1692, Dec. 2006. [CrossRef]
- S. P. Patil, P. D. Jain, P. J. Ghumatkar, R. Tambe, and S. Sathaye, “Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice,” Neuroscience, vol. 277, pp. 747–754, Sep. 2014. 2014. [CrossRef]
- W.-Y. Song et al., “Low-dose metformin treatment in the subacute phase improves the locomotor function of a mouse model of spinal cord injury,” Neural Regen. Res., vol. 16, no. 11, p. 2234, 2021. [CrossRef]
- Ben Sahra et al., “Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1,” Cancer Res., vol. 71, no. 13, pp. 4366–4372, Jul. 2011. [CrossRef]
- R. Cameron et al., “Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status,” Circ. Res., vol. 119, no. 5, pp. 652–665, Aug. 2016. [CrossRef]
- T. G. Heffner, J. A. Hartman, and L. S. Seiden, “A rapid method for the regional dissection of the rat brain,” Pharmacol. Biochem. Behav., vol. 13, no. 3, pp. 453–456, Sep. 1980. [CrossRef]
- K. J. Reissner et al., “AKAP Signaling in Reinstated Cocaine Seeking Revealed by iTRAQ Proteomic Analysis,” J. Neurosci., vol. 31, no. 15, pp. 5648–5658, Apr. 2011. [CrossRef]
- K. Lehre, L. Levy, O. Ottersen, J. Storm-Mathisen, and N. Danbolt, “Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations,” J. Neurosci., vol. 15, no. 3, pp1835–1853, Mar. 1995. [CrossRef]
- E. N. Genda et al., “Co-compartmentalization of the Astroglial Glutamate Transporter, GLT-1, with Glycolytic Enzymes and Mitochondria,” J. Neurosci., vol. 31, no. 50, pp. 18275–18288, Dec. 2011. [CrossRef]










Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).